Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 33 | 2024 | 2734 | 4.030 |
Why?
|
Immunotherapy | 19 | 2024 | 4445 | 2.070 |
Why?
|
Carcinoma, Squamous Cell | 20 | 2024 | 4034 | 2.030 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2021 | 252 | 2.010 |
Why?
|
Oropharyngeal Neoplasms | 9 | 2023 | 477 | 1.690 |
Why?
|
Radiotherapy | 7 | 2023 | 1533 | 1.550 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2022 | 806 | 1.410 |
Why?
|
Neoplasms | 23 | 2024 | 21683 | 1.300 |
Why?
|
Papillomavirus Infections | 9 | 2023 | 1587 | 1.140 |
Why?
|
Combined Modality Therapy | 17 | 2024 | 8642 | 0.990 |
Why?
|
Neoplasm Recurrence, Local | 18 | 2022 | 9239 | 0.840 |
Why?
|
Mouth Neoplasms | 4 | 2022 | 601 | 0.810 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5221 | 0.810 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11524 | 0.790 |
Why?
|
Carcinoma, Merkel Cell | 3 | 2022 | 300 | 0.730 |
Why?
|
Neoplasm Metastasis | 11 | 2022 | 4851 | 0.690 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 91 | 0.660 |
Why?
|
Melanoma | 9 | 2021 | 5510 | 0.650 |
Why?
|
Radiation Tolerance | 2 | 2023 | 486 | 0.640 |
Why?
|
Medical Futility | 1 | 2019 | 127 | 0.640 |
Why?
|
Neoadjuvant Therapy | 7 | 2023 | 2728 | 0.630 |
Why?
|
Radiotherapy Dosage | 9 | 2022 | 2879 | 0.620 |
Why?
|
Peer Review, Health Care | 1 | 2017 | 75 | 0.580 |
Why?
|
Radiation Oncology | 3 | 2017 | 555 | 0.570 |
Why?
|
Lymphopenia | 1 | 2018 | 285 | 0.550 |
Why?
|
Salivary Gland Neoplasms | 3 | 2020 | 298 | 0.540 |
Why?
|
Lung Neoplasms | 6 | 2022 | 13102 | 0.520 |
Why?
|
Tumor Microenvironment | 7 | 2023 | 3586 | 0.520 |
Why?
|
Papillomaviridae | 8 | 2022 | 1119 | 0.510 |
Why?
|
Skin Neoplasms | 7 | 2023 | 5686 | 0.500 |
Why?
|
Immunomodulation | 1 | 2019 | 541 | 0.500 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13695 | 0.490 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2015 | 358 | 0.460 |
Why?
|
Immunocompromised Host | 1 | 2019 | 847 | 0.460 |
Why?
|
Cancer Vaccines | 2 | 2011 | 1023 | 0.460 |
Why?
|
Cookbooks as Topic | 1 | 2012 | 1 | 0.450 |
Why?
|
Humans | 109 | 2024 | 744343 | 0.450 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2022 | 1624 | 0.440 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1038 | 0.440 |
Why?
|
Saliva | 1 | 2017 | 809 | 0.430 |
Why?
|
Retrospective Studies | 29 | 2023 | 77449 | 0.420 |
Why?
|
Radiation Injuries | 4 | 2021 | 1180 | 0.420 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9274 | 0.410 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2038 | 0.400 |
Why?
|
Endoribonucleases | 1 | 2013 | 229 | 0.390 |
Why?
|
Brain Neoplasms | 7 | 2021 | 8863 | 0.380 |
Why?
|
Neoplasm Staging | 12 | 2023 | 11031 | 0.380 |
Why?
|
Immunotherapy, Active | 1 | 2010 | 60 | 0.380 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2020 | 1770 | 0.370 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.370 |
Why?
|
Middle Aged | 47 | 2023 | 213383 | 0.360 |
Why?
|
Aged | 40 | 2022 | 163280 | 0.350 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2022 | 104 | 0.350 |
Why?
|
Carcinoma | 2 | 2023 | 2375 | 0.340 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 286 | 0.340 |
Why?
|
Palliative Care | 3 | 2020 | 3493 | 0.340 |
Why?
|
Radiosurgery | 4 | 2020 | 1329 | 0.340 |
Why?
|
Papillomavirus Vaccines | 1 | 2015 | 491 | 0.320 |
Why?
|
Immunophenotyping | 3 | 2018 | 1880 | 0.310 |
Why?
|
Carcinoma, Basal Cell | 2 | 2023 | 545 | 0.310 |
Why?
|
Male | 52 | 2023 | 350118 | 0.310 |
Why?
|
Appointments and Schedules | 1 | 2011 | 417 | 0.310 |
Why?
|
Food | 1 | 2012 | 771 | 0.300 |
Why?
|
Survival Analysis | 9 | 2021 | 10252 | 0.300 |
Why?
|
Pneumonia | 1 | 2019 | 2133 | 0.300 |
Why?
|
Patient Selection | 2 | 2021 | 4215 | 0.290 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1333 | 0.280 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 3703 | 0.280 |
Why?
|
Aged, 80 and over | 22 | 2021 | 57776 | 0.280 |
Why?
|
Female | 48 | 2023 | 380194 | 0.270 |
Why?
|
Pyrroles | 1 | 2012 | 1146 | 0.260 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3176 | 0.260 |
Why?
|
Carcinoma, Renal Cell | 2 | 2018 | 3143 | 0.260 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6538 | 0.250 |
Why?
|
Tumor Burden | 2 | 2021 | 1915 | 0.240 |
Why?
|
Neovascularization, Pathologic | 2 | 2011 | 2635 | 0.240 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6773 | 0.240 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12354 | 0.240 |
Why?
|
Hodgkin Disease | 1 | 2011 | 1415 | 0.230 |
Why?
|
Indoles | 1 | 2012 | 1839 | 0.230 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1061 | 0.230 |
Why?
|
Research Design | 1 | 2019 | 5987 | 0.230 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2703 | 0.230 |
Why?
|
Radiation Dosage | 2 | 2022 | 1928 | 0.220 |
Why?
|
Organs at Risk | 2 | 2022 | 346 | 0.220 |
Why?
|
Pregnancy Proteins | 1 | 2004 | 229 | 0.220 |
Why?
|
Dermatitis | 2 | 2017 | 197 | 0.210 |
Why?
|
Gadolinium | 2 | 2024 | 952 | 0.200 |
Why?
|
Prostatic Neoplasms | 5 | 2020 | 11124 | 0.200 |
Why?
|
CD8-Positive T-Lymphocytes | 5 | 2023 | 4479 | 0.200 |
Why?
|
Prognosis | 11 | 2023 | 29063 | 0.200 |
Why?
|
Nasolacrimal Duct | 1 | 2022 | 74 | 0.200 |
Why?
|
Parotid Gland | 1 | 2022 | 168 | 0.200 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9438 | 0.190 |
Why?
|
Kidney Neoplasms | 2 | 2018 | 4262 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 84 | 0.190 |
Why?
|
Immune System | 2 | 2018 | 805 | 0.190 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6895 | 0.190 |
Why?
|
Cisplatin | 3 | 2024 | 1662 | 0.190 |
Why?
|
Immunologic Factors | 2 | 2021 | 1580 | 0.190 |
Why?
|
Treatment Outcome | 15 | 2021 | 63114 | 0.190 |
Why?
|
Prostatectomy | 3 | 2014 | 1890 | 0.180 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7913 | 0.180 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 3327 | 0.170 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2021 | 286 | 0.170 |
Why?
|
Cytokines | 4 | 2019 | 7322 | 0.170 |
Why?
|
Antibody Formation | 2 | 2016 | 1402 | 0.170 |
Why?
|
Drugs, Investigational | 1 | 2021 | 214 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2282 | 0.160 |
Why?
|
Nucleic Acid Denaturation | 1 | 2018 | 111 | 0.160 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20129 | 0.160 |
Why?
|
Sarcopenia | 1 | 2023 | 368 | 0.160 |
Why?
|
Adult | 27 | 2021 | 214055 | 0.160 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6234 | 0.160 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 512 | 0.160 |
Why?
|
Survival Rate | 4 | 2018 | 12788 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2010 | 3508 | 0.150 |
Why?
|
Radiation Protection | 1 | 2021 | 419 | 0.150 |
Why?
|
Stomatitis | 1 | 2020 | 269 | 0.150 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 241 | 0.150 |
Why?
|
Mouth | 1 | 2020 | 374 | 0.150 |
Why?
|
Larynx | 1 | 2022 | 494 | 0.150 |
Why?
|
Osteoradionecrosis | 1 | 2017 | 49 | 0.140 |
Why?
|
Quality Assurance, Health Care | 2 | 2017 | 2212 | 0.140 |
Why?
|
Financial Management | 1 | 2018 | 160 | 0.140 |
Why?
|
Epirubicin | 1 | 2016 | 80 | 0.140 |
Why?
|
Lymphocyte Count | 1 | 2018 | 793 | 0.140 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 163 | 0.140 |
Why?
|
Prospective Studies | 8 | 2021 | 53288 | 0.130 |
Why?
|
Mucositis | 2 | 2019 | 101 | 0.130 |
Why?
|
Gastrointestinal Tract | 1 | 2021 | 814 | 0.130 |
Why?
|
Tooth Diseases | 1 | 2015 | 77 | 0.120 |
Why?
|
Signal Transduction | 3 | 2015 | 23403 | 0.120 |
Why?
|
Nanoparticles | 2 | 2024 | 1905 | 0.120 |
Why?
|
Chemokines | 2 | 2018 | 970 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 401 | 0.120 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12245 | 0.120 |
Why?
|
Ecosystem | 1 | 2018 | 474 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2022 | 2016 | 0.110 |
Why?
|
Creatinine | 1 | 2019 | 1919 | 0.110 |
Why?
|
Polymerase Chain Reaction | 2 | 2018 | 6171 | 0.110 |
Why?
|
Drug Carriers | 1 | 2018 | 693 | 0.110 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20822 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1097 | 0.110 |
Why?
|
Lymph Nodes | 3 | 2023 | 3474 | 0.110 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39050 | 0.110 |
Why?
|
SEER Program | 4 | 2020 | 1508 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1265 | 0.110 |
Why?
|
Information Dissemination | 1 | 2021 | 1099 | 0.110 |
Why?
|
Killer Cells, Natural | 2 | 2018 | 2133 | 0.110 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1101 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3479 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3206 | 0.100 |
Why?
|
Drug Therapy | 1 | 2015 | 497 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.100 |
Why?
|
Gastrectomy | 1 | 2016 | 663 | 0.100 |
Why?
|
Medical Oncology | 1 | 2023 | 2265 | 0.100 |
Why?
|
Computational Biology | 1 | 2004 | 3521 | 0.100 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 973 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 4456 | 0.100 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 2924 | 0.100 |
Why?
|
Interferons | 1 | 2015 | 706 | 0.100 |
Why?
|
International Cooperation | 1 | 2017 | 1420 | 0.100 |
Why?
|
Angiopoietin-1 | 1 | 2010 | 114 | 0.090 |
Why?
|
Transcription, Genetic | 2 | 2004 | 7722 | 0.090 |
Why?
|
Xerostomia | 1 | 2010 | 95 | 0.090 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 178 | 0.090 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 88 | 0.090 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1889 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1607 | 0.090 |
Why?
|
Angiopoietin-2 | 1 | 2010 | 173 | 0.090 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 629 | 0.090 |
Why?
|
Young Adult | 9 | 2021 | 56430 | 0.090 |
Why?
|
Esophagitis | 1 | 2010 | 152 | 0.090 |
Why?
|
BRCA1 Protein | 1 | 2016 | 1149 | 0.080 |
Why?
|
T-Lymphocytes | 2 | 2018 | 10180 | 0.080 |
Why?
|
Androgen Antagonists | 2 | 2020 | 1377 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 841 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 9959 | 0.080 |
Why?
|
Leadership | 1 | 2018 | 1357 | 0.080 |
Why?
|
Colitis | 1 | 2017 | 1170 | 0.080 |
Why?
|
Recurrence | 1 | 2020 | 8340 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 3255 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1692 | 0.080 |
Why?
|
Cytoskeletal Proteins | 2 | 2005 | 1364 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2645 | 0.080 |
Why?
|
Gene Library | 1 | 2010 | 1074 | 0.080 |
Why?
|
Risk Factors | 6 | 2023 | 72290 | 0.080 |
Why?
|
Carboplatin | 1 | 2010 | 801 | 0.080 |
Why?
|
Melanoma, Experimental | 1 | 2010 | 561 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1832 | 0.070 |
Why?
|
Animals | 10 | 2022 | 168757 | 0.070 |
Why?
|
Incidental Findings | 1 | 2011 | 689 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5172 | 0.070 |
Why?
|
Mucous Membrane | 2 | 2021 | 673 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 598 | 0.070 |
Why?
|
Mastectomy, Segmental | 1 | 2011 | 956 | 0.070 |
Why?
|
beta Catenin | 3 | 2006 | 1059 | 0.070 |
Why?
|
Time Factors | 3 | 2021 | 40075 | 0.070 |
Why?
|
Neutrophils | 1 | 2018 | 3719 | 0.070 |
Why?
|
Glioblastoma | 1 | 2021 | 3481 | 0.070 |
Why?
|
Developing Countries | 1 | 2017 | 2815 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2023 | 19905 | 0.060 |
Why?
|
Prostate | 1 | 2013 | 1774 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1524 | 0.060 |
Why?
|
Patient Preference | 1 | 2011 | 890 | 0.060 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2006 | 430 | 0.060 |
Why?
|
Inflammation | 2 | 2015 | 10638 | 0.060 |
Why?
|
Trans-Activators | 2 | 2005 | 2924 | 0.060 |
Why?
|
Genomics | 1 | 2020 | 5720 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 23338 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2011 | 3616 | 0.060 |
Why?
|
Philadelphia | 1 | 2023 | 266 | 0.060 |
Why?
|
Umbilical Veins | 1 | 2004 | 433 | 0.060 |
Why?
|
Paclitaxel | 1 | 2010 | 1708 | 0.060 |
Why?
|
X-Rays | 1 | 2024 | 301 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3200 | 0.050 |
Why?
|
Capillary Permeability | 1 | 2006 | 798 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2716 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11366 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8428 | 0.050 |
Why?
|
Logistic Models | 1 | 2017 | 13408 | 0.050 |
Why?
|
Genotype | 2 | 2016 | 12951 | 0.050 |
Why?
|
Culture Media | 1 | 2004 | 908 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 173 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4933 | 0.050 |
Why?
|
Cohort Studies | 4 | 2023 | 40561 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3778 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10262 | 0.050 |
Why?
|
Genetic Variation | 1 | 2016 | 6544 | 0.050 |
Why?
|
Mice | 5 | 2022 | 81183 | 0.050 |
Why?
|
Endothelium | 1 | 2003 | 778 | 0.050 |
Why?
|
Antigens, CD | 1 | 2010 | 4026 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2416 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2024 | 2327 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 379 | 0.040 |
Why?
|
Hypokalemia | 1 | 2019 | 153 | 0.040 |
Why?
|
Algorithms | 2 | 2023 | 13881 | 0.040 |
Why?
|
Disease Progression | 3 | 2020 | 13284 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2018 | 370 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 15519 | 0.040 |
Why?
|
Jaw | 1 | 2017 | 96 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 892 | 0.040 |
Why?
|
Obesity | 1 | 2019 | 12745 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 876 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 402 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2018 | 399 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1643 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7279 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2020 | 1097 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2274 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1275 | 0.030 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 312 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1842 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 463 | 0.030 |
Why?
|
Workflow | 1 | 2018 | 847 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2022 | 2480 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2006 | 3479 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2010 | 6364 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 502 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 705 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 16718 | 0.030 |
Why?
|
Diarrhea | 1 | 2019 | 1348 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2018 | 5974 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2020 | 2187 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2006 | 19229 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 20947 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 1836 | 0.020 |
Why?
|
Swine | 1 | 2021 | 5917 | 0.020 |
Why?
|
Breast | 1 | 2020 | 1969 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2021 | 8301 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4397 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12026 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2022 | 3690 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4186 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2046 | 0.020 |
Why?
|
United States | 2 | 2019 | 69872 | 0.020 |
Why?
|
Documentation | 1 | 2015 | 871 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7301 | 0.020 |
Why?
|
Proteins | 1 | 2004 | 6103 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2043 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5300 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5524 | 0.020 |
Why?
|
Histamine Agents | 1 | 2006 | 3 | 0.020 |
Why?
|
Blotting, Western | 2 | 2006 | 5179 | 0.020 |
Why?
|
Decision Making | 1 | 2021 | 3887 | 0.020 |
Why?
|
Receptors, Histamine | 1 | 2006 | 22 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2219 | 0.020 |
Why?
|
DNA Damage | 1 | 2016 | 2432 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6756 | 0.020 |
Why?
|
gamma Catenin | 1 | 2005 | 44 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 12072 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2948 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4386 | 0.020 |
Why?
|
Desmoplakins | 1 | 2005 | 62 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10397 | 0.020 |
Why?
|
Phosphoserine | 1 | 2005 | 206 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 6933 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2278 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 35421 | 0.020 |
Why?
|
Histamine | 1 | 2006 | 507 | 0.020 |
Why?
|
Rats | 1 | 2021 | 24260 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11483 | 0.020 |
Why?
|
Base Sequence | 1 | 2016 | 12797 | 0.020 |
Why?
|
Quality Improvement | 1 | 2019 | 3749 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3597 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8089 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 12804 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 829 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18029 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2006 | 2505 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3507 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 12720 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2005 | 1526 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12959 | 0.010 |
Why?
|
Exons | 1 | 2005 | 2437 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15076 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9648 | 0.010 |
Why?
|
Cytoplasm | 1 | 2003 | 1539 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4468 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2006 | 2503 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2006 | 2938 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2003 | 3144 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2003 | 2699 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4568 | 0.010 |
Why?
|
Actins | 1 | 2003 | 2121 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 6622 | 0.010 |
Why?
|
Phosphorylation | 1 | 2006 | 8436 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 5892 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 29786 | 0.010 |
Why?
|
Protein Binding | 1 | 2005 | 9386 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15997 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 9583 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2003 | 14557 | 0.000 |
Why?
|
Adolescent | 1 | 2015 | 85781 | 0.000 |
Why?
|
Lung | 1 | 2003 | 9856 | 0.000 |
Why?
|